Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2011-03-29
2011-03-29
Ouspenski, Ilia (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Reexamination Certificate
active
07914786
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage.
REFERENCES:
patent: 5780263 (1998-07-01), Hastings et al.
patent: 6395511 (2002-05-01), Brunkow et al.
patent: 6489445 (2002-12-01), Brunkow et al.
patent: 6495736 (2002-12-01), Brunkow et al.
patent: 6803453 (2004-10-01), Brunkow et al.
patent: 6875570 (2005-04-01), Gerlach et al.
patent: 7585501 (2009-09-01), Krumlauf et al.
patent: 2003/0166247 (2003-09-01), Brunkow et al.
patent: 2008/0160060 (2008-07-01), Ellies
patent: WO 00/32773 (2000-06-01), None
Capecchi, “Targeted Gene Replacement,” Scientific American, vol. 270, No. 3, pp. 52-59 (1994).
Houdebine, “Production Of Pharmaceutical Proteins From Transgenic Animals,” J. Biotech, vol. 34, pp. 269-287 (1994).
Wall, “Transgenic Livestock: Progress And Prospects For The Future,” Theriogenology, vol. 45, pp. 57-68 (1996).
Niemann, “Transgenic Farm Animals Get Off The Ground. Transgenic Animals In Agriculture,” Transg. Res., vol. 7, pp. 73-75 (1998).
Keri et al., “Luteinizing Hormone Induction Of Ovarian Tumors: Oligogenic Differences Between Mouse Strains Dictates Tumor Disposition,” PNAS, vol. 97, No. 1, pp. 383-387 (2000).
Brunkow et al., “Bone Dysplasia Sclerosteosis Results From Loss Of The SOST Gene Product, A Novel Cysteine Knot-Containing Protein,” Am. J. Hum. Genet., vol. 68, pp. 577-589 (2001).
Balmain et al., “Cancer Resistance Genes In Mice: Models For The Study Of Tumour Modifiers,” Trends in Genetics, vol. 14, No. 4, pp. 139-144 (1998).
Cameron, “Recent Advances In Transgenic Technology,” Molec. Biol., vol. 7, pp. 253-265 (1997).
Aubin et al., “Monoclonal Antibodies as Tools for Studying the Osteoblast Lineage,” Microscopy Research and Technique, vol. 33, pp. 128-140 (1996).
Bachiller et al., “The Organizer Factors Chordin and Noggin Are Required For Mouse Forebrain Development,” Nature, vol. 403, pp. 658-661 (2000).
Balemans et al., “Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators,” Developmental Biology , vol. 250, pp. 231-250 (2002).
Balemans et al., “Increased Bone Density In Sclerosteosis Is Due to the Deficiency Of A Novel Secreted Protein (SOST),” Human Molecular Genetics, vol. 10, No. 5, pp. 537-543 (2001).
Bork, “The Modular Architecture Of A New Family Of Growth Regulators Related to Connective Tissue Growth Factor,” FEBS Letters, vol. 327, No. 2, pp. 125-130 (1993).
Boyden et al., “High Bone Density Due to a Mutation in LOL-Receptor-Related Protein 5,” The New England Journal of Medicine, vol. 346, No. 20, pp. 1513-1521 (2002).
Bruder et al., “Monoclonal Antibodies Reactive With Human Osteogenic Cell Surface Antigens,” Bone, vol. 21, No. 3, pp. 225-235 (1997).
Brunkow et al., “Bone Dysplasla Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot-Containing Protein,” Am. J. Hum. Genet., vol. 68, pp. 577-589 (2001).
Chen et al., “Thy-1 Antigen Expression By Cells in the Osteoblast Lineage,” Journal of Bone and Mineral Research, vol. 14, No. 3, pp. 362-375 (1999).
Dewitt, “Bone and Cartilage,” Nature, vol. 423, p. 315 (2003).
Gong et al., “LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development,” Cell, vol. 107, pp. 513-523 (2001).
Hamersma et al., “The Natural History of Sclerosteosis;” Clinical Genetics, vol. 63, pp. 192-197 (2003).
Harada et al., “Control Of Osteoblast Function and Regulation of Bone Mass,” Nature, vol. 423, pp. 349-355 (2003).
Harris et al., “Human Fetal Osteoblast Progenitor Cell Lines (hFOB),” http.//www.mayo.edutachcomm/93010.html, visited Jun. 11, 2003.
Hartley et al., “Targeted Gene Expression In Transgenic Xenopus Using The Binary Ga14-UAS System,” Proc. Natl. Acad. Sci., vol. 99, No. 3, pp. 1377-1382 (2002).
Hartmann, “Wnt-Signaling and Skeletogenesis,” J. Musculoskel. Neuron Interact., vol. 2, No. 3, pp. 274-276 (2002).
Hemmati-Brivanlou, “Vertebrate Neural Induction,” Annual Review Neuroscience, vol. 20, pp. 43-60 (1997).
Hoppler, “Wnt Signalling in Xenopus Development,” http://www.personal.dundee.ac.uk/-sphopple/research.html, visited on May 1, 2002.
Itasaki et al., “Wise, A Context-Dependent Activator and Inhibitor Of Wnt Signaling,” Development, vol. 130, pp. 4295 4305 (2003).
Ivkovic et al., “Connective Tissue Growth Factor Coordinates Chondrogenesis and Angiogenesis During Skeletal Development,” Development, vol. 130, pp. 2779-2791 (2003).
Karsenty, “The Complexities Of Skeletal Biology,” Nature, vol. 423, pp. 316-318 (2003).
Kato et al., “Cbfa1-Independent Decrease In Osteoblast Proliferation, Osteopenia, and Persistent Embryonic Eye Vascularization in Mice Deficient in Lrp5, A Wnt Coreceptor,” The Journal of Cell Biology, vol. 157, No. 2, pp. 303-314 (2002).
Kerszberg et al., “A Simple Molecular Model Of Neurulation,” BioEssays, vol. 20, pp. 758-770 (1998).
Kronenberg et al., “Developmental Regulation Of the Growth Plate,” Nature, vol. 423, pp. 332-338 (2003).
Kusu et al., “Sclerostin is a Novel Secreted Osteoclast-Derived Bone Morphogenetic Protein (BMP) Antagonist with Unique Ligand Specificity,” The American Society for Biochemistry and Molecular Biology, Inc., (Manuscript) M301716200 (Apr. 17, 2003).
Latinkic et al., “Xenopus Cyr61 Regulates Gastrulation Movements and Modulates Wnt Signalling,” Development, vol. 130, pp. 2429-2441 (2003).
Little et al., “A Mutation in the LDL Receptor-Related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait,” The American Journal of Human Genetics, vol. 70, pp. 11-19 (2002).
Little et al., “High Bone Density Due to a Mutation in LDL-Receptor-Related Protein 5,” The New England Journal of Medicine, vol. 347, No. 12, pp. 943-944 (2002).
Mao et al., “LDL-Receptor-Related Protein 6 Is A Receptor For Dickkopf Proteins,” Nature, vol. 411, pp. 321-325 (2001).
Mathis et al., “Pre-Steady-State Study of Recombinant Sesquiterpene Cyclases,” Biochemistry, vol. 38, pp. 8340-8348 (1997).
McClary et al., “The Effects of Ascorbic Acid on the Osteoblast Extracellular Matrix,” http:/lsvl.Ia.asu.edu/ubep2001/abstracts/mcclaryl, visited on Jun. 11, 2003.
McMahon et al., “Noggin-Mediated Antagonism Of BMP Signaling Is Required For Growth and Patterning Of The Neural Tube and Somite,” Genes & Development, vol. 12, pp. 1438-1452 (1998).
Meitinger et al., “Molecular Modelling Of The Norrie Disease Protein Predicts A Cystine Knot Growth Factor Tertiary Structure,” Nature Genetics, vol. 5, pp. 376-380 (1993).
Nijweide et al., “Identification Of Osteocytes In Osteoblast-Like Cell Cultures Using A Monoclonal Antibody Specifically Directed Against Osteocytes,” Histochemistry, vol. 84, pp. 342-347 (1986).
Prince et al., “Hox Gene Expression Reveals Regionalization Along The Anteroposterior Axis Of the Zebrafish Notochord,” Dev. Genes Evol., vol. 208, pp. 517-522 (1998).
Rosen et al., “Defining the Genetics of Osteoporosis: Using the Mouse to Understand Man,” Osteoporosis International, vol. 12, pp. 803-810 (2001).
Segarini et al., “The Low Density Lipoprotein Receptor-Related Protein/alpha2-Macroglobulin Receptor is a Receptor for Connective Tissue Growth Factor (CTGF),” The American Society for Biochemistry and Molecular Biology, Inc., (Manuscript) M105180200 (2001).
Simmons et al., “Uterine Sensitization-Associated Gene-1: A Novel Gene Induced Within the Rat Endometrium at
Ellies Debra
Krumlauf Robb
Bryan Cave LLP
Ouspenski Ilia
Stowers Institute for Medical Research
LandOfFree
Compositions and methods for treating kidney disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treating kidney disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treating kidney disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2696408